Kolexia
Driouich Jean-Sélim
Pharmacien
Institut Hospitalo Universitaire - Méditerranée Infection
Marseille, France
24 Activités
33 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} COVID-19 Entorses et foulures Encéphalites à tiques Encéphalite Diarrhée Fièvre chikungunya Infections à virus à ARN Entérite Co-infection

Industries

{{person.topindus1.name}}
{{person.topindus1.tot}} collaboration(s)
Dernière en {{person.topindus1.last}}
{{person.topindus2.name}}
{{person.topindus2.tot}} collaboration(s)
Dernière en {{person.topindus2.last}}
{{person.topindus3.name}}
{{person.topindus3.tot}} collaboration(s)
Dernière en {{person.topindus3.last}}
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strains.
Antiviral research   24 janvier 2024
Simultaneous quantitation of favipiravir and its hydroxide metabolite in human plasma and hamster matrices using a UPLC-MS/MS method.
Biomedical chromatography : BMC   22 juin 2023
Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model.
Antiviral research   18 mai 2023
Need for a Standardized Translational Drug Development Platform: Lessons Learned from the Repurposing of Drugs for COVID-19.
Microorganisms   12 août 2022
Pre-clinical evaluation of antiviral activity of nitazoxanide against SARS-CoV-2.
EBioMedicine   11 juillet 2022
The SARS-CoV-2 Alpha variant exhibits comparable fitness to the D614G strain in a Syrian hamster model.
Communications biology   10 mars 2022
A simple reverse genetics method to generate recombinant coronaviruses.
EMBO reports   03 mars 2022
Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster model.
Antiviral research   24 novembre 2021
Investigation of Bufavirus and Parvovirus 4 in Patients with Gastro-Enteritis from the South-East of France.
Pathogens (Basel, Switzerland)   07 septembre 2021
Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2.
Antiviral research   12 juillet 2021